Bullish Options Activity in Las Vegas Sands (LVS) Targets 6% Upside in Shares Through Mid-September -Susquehanna
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Oil market losses easing as nearly 80% of disrupted supply returns, UBS says
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Pre-Open Stock Movers 04/18: (MBIO) (URI) (CGC) Higher; (ATNM) (SNBR) (TEAM) Lower (more...)
April 18, 2019 9:21 AM EDTToday's Pre-Open Stock Movers
Mustang Bio, Inc. (Mustang) (NASDAQ: MBIO) 200.8% HIGHER; Announced that the New England Journal of Medicine has published data from St. Jude Childrens Research Hospital (St. Jude), the nations leading hospital dedicated to understanding, treating and curing childhood cancer and other life-threatening diseases. The data comes from a Phase 1/2 clinical trial of a lentiviral gene therapy for the treatment of newly diagnosed infants under two years old with XSCID, also referred to as SCID-X1 and commonly known as bubble boy disease. Under a licensing... More
Las Vegas Sands (LVS) PT Raised to $71 at Morgan Stanley
April 18, 2019 9:00 AM EDTMorgan Stanley analyst Thomas Allen raised the price target on Las Vegas Sands (NYSE: LVS) to $71.00 (from $66.00) while maintaining a Overweight rating.
... MoreLas Vegas Sands (LVS) PT Raised to $80 at Stifel
April 18, 2019 7:20 AM EDTStifel analyst Steven Wieczynski raised the price target on Las Vegas Sands (NYSE: LVS) to $80.00 (from $72.00) while maintaining a Buy rating.
... MoreLas Vegas Sands (LVS) PT Raised to $80 at Union Gaming
April 18, 2019 7:18 AM EDTUnion Gaming analyst John DeCree raised the price target on Las Vegas Sands (NYSE: LVS) to $80.00 while maintaining a Buy rating.
... MoreLas Vegas Sands (LVS) PT Raised to $72 at BofA/Merrill Lynch
April 18, 2019 6:48 AM EDTBofA/Merrill Lynch analyst Shaun Kelley raised the price target on Las Vegas Sands (NYSE: LVS) to $72.00 (from $70.00) while maintaining a Neutral rating.
... MoreLas Vegas Sands (LVS) PT Raised to $69 at Deutsche Bank
April 18, 2019 6:47 AM EDTDeutsche Bank analyst Carlo Santarelli raised the price target on Las Vegas Sands (NYSE: LVS) to $69.00 (from $60.00) while maintaining a Hold rating.
... MoreLas Vegas Sands (LVS) PT Raised to $71 at Morgan Stanley
April 18, 2019 6:41 AM EDTMorgan Stanley analyst Thomas Allen raised the price target on Las Vegas Sands (NYSE: LVS) to $71.00 (from $66.00) while maintaining a Overweight rating.
... MoreLas Vegas Sands (LVS) PT Raised to $73 at Macquarie
April 18, 2019 2:59 AM EDTMacquarie analyst Chad Beynon raised the price target on Las Vegas Sands (NYSE: LVS) to $73.00 (from $70.00) while maintaining a Outperform rating.
... MoreAfter-Hours Movers 04/17: (MBIO) (URI) (CGC) Higher; (ATNM) (SNBR) (TEAM) (more...)
April 17, 2019 5:49 PM EDTToday's After-Hours
Mustang Bio, Inc. (Mustang) (NASDAQ: MBIO) 167% HIGHER; Announced that the New England Journal of Medicine has published data from St. Jude Childrens Research Hospital (St. Jude), the nations leading hospital dedicated to understanding, treating and curing childhood cancer and other life-threatening diseases. The data comes from a Phase 1/2 clinical trial of a lentiviral gene therapy for the treatment of newly diagnosed infants under two years old with XSCID, also referred to as SCID-X1 and commonly known as bubble boy disease. Under a licensing agreement with St.... More
Las Vegas Sands (LVS) Tops Q1 EPS by 5c
April 17, 2019 4:06 PM EDTLas Vegas Sands (NYSE: LVS) reported Q1 EPS of $0.91, $0.05 better than the analyst estimate of $0.86. Revenue for the quarter came in at $3.65 billion versus the consensus estimate of $3.47 billion.
Consolidated Adjusted Property EBITDA of $1.45 Billion- In Macao, Adjusted Property EBITDA Increased 8.7% to $858 Million, While... MoreHSBC Downgrades Las Vegas Sands (LVS) to Hold
April 17, 2019 9:33 AM EDTHSBC downgraded Las Vegas Sands (NYSE: LVS) from Buy to Hold with a price target of $65.40 (from $69.50).
For an analyst ratings summary and ratings history on Las Vegas Sands click here. For more ratings news on Las Vegas Sands click here.
Shares of Las Vegas Sands closed at $68.16 yesterday.
... More